Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Treasury Shares (2019 - 2025)

Keros Therapeutics filings provide 3 years of Treasury Shares readings, the most recent being $21.1 million for Q4 2025.

  • On a quarterly basis, Treasury Shares changed N/A to $384.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $384.6 million, a N/A change, with the full-year FY2025 number at $384.6 million, changed N/A from a year prior.
  • Treasury Shares hit $384.6 million in Q4 2025 for Keros Therapeutics.
  • In the past five years, Treasury Shares ranged from a high of $21.1 million in Q4 2025 to a low of $721700.0 in Q3 2025.